The importance of immune checkpoints in immune monitoring: A future paradigm shift in the treatment of cancer

The blockade of immune checkpoints in cancer immunotherapy

Pardoll, D. M. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3239 · Cited by 13,838 · see citing works

Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer

Brahmer, J., Reckamp, K. L., Baas, P., Crinò, L., Eberhardt, W. E. E., Poddubskaya, E., Antonia, S., Pluzanski, A., Vokes, E. E., Holgado, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504627 · Cited by 8,447 · see citing works

Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma

Larkin, J., Chiarion-Sileni, V., Gonzalez, R., Grob, J. J., Cowey, C. L., Lao, C. D., Schadendorf, D., Dummer, R., Smylie, M., Rutkowski, P., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504030 · Cited by 8,157 · see citing works

Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer

Rizvi, N. A., Hellmann, M. D., Snyder, A., Kvistborg, P., Makarov, V., Havel, J. J., Lee, W., Yuan, J., Wong, P., Ho, T. S., et al. (2015) · Science · doi:10.1126/science.aaa1348 · Cited by 7,802 · see citing works

Cancer immunotherapy using checkpoint blockade

Ribas, A., & Wolchok, J. D. (2018) · Science · doi:10.1126/science.aar4060 · Cited by 6,791 · see citing works

Myeloid-derived-suppressor cells as regulators of the immune system

Gabrilovich, D. I., & Nagaraj, S. (2009) · Nature Reviews Immunology · doi:10.1038/nri2506 · Cited by 6,753 · see citing works

Cancer Immunoediting: Integrating Immunity’s Roles in Cancer Suppression and Promotion

Schreiber, R. D., Old, L. J., & Smyth, M. J. (2011) · Science · doi:10.1126/science.1203486 · Cited by 6,474 · see citing works

Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma

Motzer, R. J., Escudier, B., McDermott, D. F., George, S., Hammers, H. J., Srinivas, S., Tykodi, S. S., Sosman, J. A., Procopio, G., Plimack, E. R., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1510665 · Cited by 5,807 · see citing works

Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck

Ferris, R. L., Blumenschein, G., Fayette, J., Guigay, J., Colevas, A. D., Licitra, L., Harrington, K., Kasper, S., Vokes, E. E., Even, C., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1602252 · Cited by 5,101 · see citing works

Durvalumab after chemoradiotherapy in stage III non–small-cell lung cancer

Antonia, S. J., Villegas, A., Daniel, D., Vicente, D., Murakami, S., Hui, R., Yokoi, T., Chiappori, A., Lee, K. H., de Wit, M., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1709937 · Cited by 4,593 · see citing works

Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma

Robert, C., Thomas, L., Bondarenko, I., O'Day, S., Weber, J., Garbe, C., Lebbe, C., Baurain, J.-F., Testori, A., Grob, J.-J., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1104621 · Cited by 4,496 · see citing works

Nivolumab plus Ipilimumab in Advanced Melanoma

Wolchok, J. D., Kluger, H., Callahan, M. K., Postow, M. A., Rizvi, N. A., Lesokhin, A. M., Segal, N. H., Ariyan, C. E., Gordon, R.-A., Reed, K., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1302369 · Cited by 4,230 · see citing works

Immune Checkpoint Blockade: A Common Denominator Approach to Cancer Therapy

Topalian, S. L., Drake, C. G., & Pardoll, D. M. (2015) · Cancer Cell · doi:10.1016/j.ccell.2015.03.001 · Cited by 4,229 · see citing works

IFN-γ–related mRNA profile predicts clinical response to PD-1 blockade

Ayers, M., Lunceford, J., Nebozhyn, M., Murphy, E., Loboda, A., Kaufman, D. R., Albright, A., Cheng, J. D., Kang, S. P., Shankaran, V., et al. (2017) · Journal of Clinical Investigation · doi:10.1172/jci91190 · Cited by 3,788 · see citing works

Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma

Bellmunt, J., de Wit, R., Vaughn, D. J., Fradet, Y., Lee, J.-L., Fong, L., Vogelzang, N. J., Climent, M. A., Petrylak, D. P., Choueiri, T. K., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1613683 · Cited by 3,395 · see citing works

Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma

Zaretsky, J. M., Garcia-Diaz, A., Shin, D. S., Escuin-Ordinas, H., Hugo, W., Hu-Lieskovan, S., Torrejon, D. Y., Abril-Rodriguez, G., Sandoval, S., Barthly, L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1604958 · Cited by 3,237 · see citing works

Molecular mechanisms of T cell co-stimulation and co-inhibition

Chen, L., & Flies, D. B. (2013) · Nature Reviews Immunology · doi:10.1038/nri3405 · Cited by 3,114 · see citing works

Regulatory T cells: mechanisms of differentiation and function

Josefowicz, S. Z., Lu, L.-F., & Rudensky, A. Y. (2012) · Annual Review of Immunology · doi:10.1146/annurev.immunol.25.022106.141623 · Cited by 2,866 · see citing works

Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial

Weber, J. S., D’Angelo, S. P., Minor, D. R., Hodi, F. S., Gutzmer, R., Neyns, B., Höeller, C., Khushalani, N. I., Miller, W. H., Lao, C. D., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)70076-8 · Cited by 2,676 · see citing works

Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer

Twyman-Saint Victor, C., Rech, A. J., Maity, A., Rengan, R., Pauken, K. E., Stelekati, E., Benci, J. L., Xu, B., Dada, H., Odorizzi, P. M., et al. (2015) · Nature · doi:10.1038/nature14292 · Cited by 2,434 · see citing works

PD-1 expression by tumour-associated macrophages inhibits phagocytosis and tumour immunity

Gordon, S. R., Maute, R. L., Dulken, B. W., Hutter, G., George, B. M., McCracken, M. N., Gupta, R., Tsai, J. M., Sinha, R., Corey, D., et al. (2017) · Nature · doi:10.1038/nature22396 · Cited by 2,247 · see citing works

PD-L1 is a novel direct target of HIF-1α, and its blockade under hypoxia enhanced: MDSC-mediated T cell activation

Noman, M. Z., Desantis, G., Janji, B., Hasmim, M., Karray, S., Dessen, P., Bronte, V., & Chouaib, S. (2014) · Journal of Experimental Medicine · doi:10.1084/jem.20131916 · Cited by 2,166 · see citing works

PD-L1 regulates the development, maintenance, and function of induced regulatory T cells

Francisco, L. M., Salinas, V. H., Brown, K. E., Vanguri, V. K., Freeman, G. J., Kuchroo, V. K., & Sharpe, A. H. (2009) · The Journal of Experimental Medicine · doi:10.1084/jem.20090847 · Cited by 2,072 · see citing works

The Tim-3 ligand galectin-9 negatively regulates T helper type 1 immunity

Zhu, C., Anderson, A. C., Schubart, A., Xiong, H., Imitola, J., Khoury, S. J., Zheng, X. X., Strom, T. B., & Kuchroo, V. K. (2005) · Nature Immunology · doi:10.1038/ni1271 · Cited by 2,057 · see citing works

Immune checkpoint inhibitors: recent progress and potential biomarkers

Darvin, P., Toor, S. M., Sasidharan Nair, V., & Elkord, E. (2018) · Experimental & Molecular Medicine · doi:10.1038/s12276-018-0191-1 · Cited by 2,035 · see citing works

The Nature of Myeloid-Derived Suppressor Cells in the Tumor Microenvironment

Kumar, V., Patel, S., Tcyganov, E., & Gabrilovich, D. I. (2016) · Trends in Immunology · doi:10.1016/j.it.2016.01.004 · Cited by 2,008 · see citing works

Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group

on behalf of the Society for Immunotherapy of Cancer Toxicity Management Working Group, Puzanov, I., Diab, A., Abdallah, K., Bingham, C. O., Brogdon, C., Dadu, R., Hamad, L., Kim, S., Lacouture, M. E., et al. (2017) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-017-0300-z · Cited by 1,992 · see citing works

PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors

Curran, M. A., Montalvo, W., Yagita, H., & Allison, J. P. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0915174107 · Cited by 1,874 · see citing works

Safety and Efficacy of Pembrolizumab Monotherapy in Patients With Previously Treated Advanced Gastric and Gastroesophageal Junction Cancer: Phase 2 Clinical KEYNOTE-059 Trial

Fuchs, C. S., Doi, T., Jang, R. W., Muro, K., Satoh, T., Machado, M., Sun, W., Jalal, S. I., Shah, M. A., Metges, J.-P., et al. (2018) · JAMA Oncology · doi:10.1001/jamaoncol.2018.0013 · Cited by 1,784 · see citing works

Myeloid-derived suppressor cells coming of age

Veglia, F., Perego, M., & Gabrilovich, D. I. (2018) · Nature Immunology · doi:10.1038/s41590-017-0022-x · Cited by 1,766 · see citing works

Myeloid-Derived Suppressor Cells: Linking Inflammation and Cancer

Ostrand‐Rosenberg, S., & Sinha, P. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0802740 · Cited by 1,733 · see citing works

Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial

Ribas, A., Puzanov, I. J., Dummer, R., Schadendorf, D., Hamid, O., Robert, C., Hodi, F. S., Schachter, J., Pavlick, A. C., Lewis, K. D., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00083-2 · Cited by 1,580 · see citing works

The surface protein TIGIT suppresses T cell activation by promoting the generation of mature immunoregulatory dendritic cells

Yu, X., Harden, K., Gonzalez, L. C., Francesco, M. R., Chiang, E. Y., Irving, B. A., Tom, I., Ivelja, S., Refino, C. J., Clark, H. F., et al. (2008) · Nature Immunology · doi:10.1038/ni.1674 · Cited by 1,486 · see citing works

Cancer immunotherapy: harnessing the immune system to battle cancer

Yang, Y. (2015) · Journal of Clinical Investigation · doi:10.1172/jci83871 · Cited by 1,366 · see citing works

CSF1/CSF1R blockade reprograms tumor-infiltrating macrophages and improves response to T-cell checkpoint immunotherapy in pancreatic cancer models

Zhu, Y., Knolhoff, B. L., Meyer, M. A., Nywening, T. M., West, B. L., Luo, J., Wang-Gillam, A., Goedegebuure, S. P., Linehan, D. C., & DeNardo, D. G. (2014) · Cancer Research · doi:10.1158/0008-5472.can-13-3723 · Cited by 1,324 · see citing works

Distinct cellular mechanisms underlie anti-CTLA-4 and anti-PD-1 checkpoint blockade

Wei, S. C., Levine, J. H., Cogdill, A. P., Zhao, Y., Anang, N.-A. A. S., Andrews, M. C., Sharma, P., Wang, J., Wargo, J. A., Pe’er, D., et al. (2017) · Cell · doi:10.1016/j.cell.2017.07.024 · Cited by 1,302 · see citing works

Loss of IFN-γ pathway genes in tumor cells as a mechanism of resistance to anti-CTLA-4 therapy

Gao, J., Shi, L. Z., Zhao, H., Chen, J., Xiong, L., He, Q., Chen, T., Roszik, J., Bernatchez, C., Woodman, S. E., et al. (2016) · Cell · doi:10.1016/j.cell.2016.08.069 · Cited by 1,300 · see citing works

Anti-NKG2A mAb Is a Checkpoint Inhibitor that Promotes Anti-tumor Immunity by Unleashing Both T and NK Cells

André, P., Denis, C., Soulas, C., Bourbon, C., Lopez, J., Arnoux, T., Bléry, M., Bonnafous, C., Gauthier, L., Morel, A., et al. (2018) · Cell · doi:10.1016/j.cell.2018.10.014 · Cited by 1,229 · see citing works

Overcoming T cell exhaustion in infection and cancer

Pauken, K. E., & Wherry, E. J. (2015) · Trends in Immunology · doi:10.1016/j.it.2015.02.008 · Cited by 1,178 · see citing works

NK cells and cancer: you can teach innate cells new tricks

Morvan, M. G., & Lanier, L. L. (2015) · Nature reviews. Cancer · doi:10.1038/nrc.2015.5 · Cited by 1,159 · see citing works

T-cell exhaustion in the tumor microenvironment

Jiang, Y., Li, Y., & Zhu, B. (2015) · Cell Death and Disease · doi:10.1038/cddis.2015.162 · Cited by 1,151 · see citing works

PI3Kγ is a molecular switch that controls immune suppression

Kaneda, M. M., Messer, K., Ralainirina, N., Li, H., Leem, C. J., Gorjestani, S., Woo, G., Nguyen, A. V., Figueiredo, C. C., Foubert, P., et al. (2016) · Nature · doi:10.1038/nature19834 · Cited by 1,118 · see citing works

Resistance Mechanisms to Immune-Checkpoint Blockade in Cancer: Tumor-Intrinsic and -Extrinsic Factors

Pitt, J. M., Vétizou, M., Daillère, R., Roberti, M. P., Yamazaki, T., Routy, B., Lepage, P., Boneca, I. G., Chamaillard, M., Kroemer, G., et al. (2016) · Immunity · doi:10.1016/j.immuni.2016.06.001 · Cited by 1,040 · see citing works

PD-1 + regulatory T cells amplified by PD-1 blockade promote hyperprogression of cancer

Kamada, T., Togashi, Y., Tay, C., Ha, D., Sasaki, A., Nakamura, Y., Sato, E., Fukuoka, S., Tada, Y., Tanaka, A., et al. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1822001116 · Cited by 1,006 · see citing works

Phase II Study of the Efficacy and Safety of Pembrolizumab for Relapsed/Refractory Classic Hodgkin Lymphoma

Chen, R., Zinzani, P. L., Fanale, M. A., Armand, P. A., Johnson, N. A., Brice, P., Radford, J. A., Ribrag, V., Molin, D. L., Vassilakopoulos, T. P., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.72.1316 · Cited by 991 · see citing works

A clinical trial of CTLA-4 blockade with tremelimumab in patients with hepatocellular carcinoma and chronic hepatitis C

Sangro, B., Gómez-Martín, C., de la Mata, M., Iñarrairaegui, M., Garralda, E., Barrera, P., Riezu‐Boj, J. I., Larrea, E., Alfaro, C., Sarobe, P., et al. (2013) · Journal of Hepatology · doi:10.1016/j.jhep.2013.02.022 · Cited by 981 · see citing works

Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti-CTLA-4 antibodies

Peggs, K. S., Quezada, S. A., Chambers, C. A., Korman, A. J., & Allison, J. P. (2009) · Journal of Experimental Medicine · doi:10.1084/jem.20082492 · Cited by 967 · see citing works

Immunogenic Chemotherapy Sensitizes Tumors to Checkpoint Blockade Therapy

Pfirschke, C., Engblom, C., Rickelt, S., Cortez‐Retamozo, V., Garris, C., Pucci, F., Yamazaki, T., Poirier-Colame, V., Newton, A., Redouane, Y., et al. (2016) · Immunity · doi:10.1016/j.immuni.2015.11.024 · Cited by 944 · see citing works

Natural killer cells, viruses and cancer

Cerwenka, A., & Lanier, L. L. (2001) · Nature reviews. Immunology · doi:10.1038/35095564 · Cited by 874 · see citing works

Tumor-infiltrating NY-ESO-1–specific CD8 ⁺ T cells are negatively regulated by LAG-3 and PD-1 in human ovarian cancer

Matsuzaki, J., Gnjatic, S., Mhawech-Fauceglia, P., Beck, A., Miller, A., Tsuji, T., Eppolito, C., Qian, F., Lele, S., Shrikant, P., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1003345107 · Cited by 859 · see citing works

Antitumor Activity of Pembrolizumab in Biomarker-Unselected Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma: Results From the Phase Ib KEYNOTE-012 Expansion Cohort

Chow, L. Q. M., Haddad, R. I., Gupta, S., Mahipal, A., Mehra, R., Tahara, M., Berger, R., Eder, J. P., Burtness, B. A., Lee, S., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.68.1478 · Cited by 859 · see citing works

Tumor-associated macrophages: from basic research to clinical application

Yang, L., & Zhang, Y. (2017) · Journal of Hematology & Oncology · doi:10.1186/s13045-017-0430-2 · Cited by 847 · see citing works

The PD-1 expression balance between effector and regulatory T cells predicts the clinical efficacy of PD-1 blockade therapies

Kumagai, S., Togashi, Y., Kamada, T., Sugiyama, E., Nishinakamura, H., Takeuchi, Y., Kochin, V., Itahashi, K., Maeda, Y., Matsui, S., et al. (2020) · Nature Immunology · doi:10.1038/s41590-020-0769-3 · Cited by 794 · see citing works

TIGIT and PD-1 impair tumor antigen–specific CD8+ T cells in melanoma patients

Chauvin, J.-M., Pagliano, O., Fourcade, J. J., Sun, Z., Wang, H., Sander, C., Kirkwood, J. M., Chen, T.-H. T., Maurer, M. F., Korman, A. J., et al. (2015) · Journal of Clinical Investigation · doi:10.1172/jci80445 · Cited by 785 · see citing works

An immune-active tumor microenvironment favors clinical response to ipilimumab

Ji, R., Chasalow, S. D., Wang, L., Hamid, O., Schmidt, H., Cogswell, J. P., Alaparthy, S., Berman, D., Jure‐Kunkel, M., Siemers, N. O., et al. (2011) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-011-1172-6 · Cited by 771 · see citing works

T cell anergy, exhaustion, senescence, and stemness in the tumor microenvironment

Crespo, J., Sun, H., Welling, T. H., Tian, Z., & Zou, W. (2013) · Current Opinion in Immunology · doi:10.1016/j.coi.2012.12.003 · Cited by 752 · see citing works

Immune checkpoint inhibitors of PD-L1 as cancer therapeutics

Akinleye, A., & Rasool, Z. (2019) · Journal of Hematology & Oncology · doi:10.1186/s13045-019-0779-5 · Cited by 743 · see citing works

Cancer immunotherapy: Pros, cons and beyond

Tan, S., Li, D., & Zhu, X. M. (2020) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2020.109821 · Cited by 694 · see citing works

Tumor-Evoked Regulatory B Cells Promote Breast Cancer Metastasis by Converting Resting CD4+ T Cells to T-Regulatory Cells

Olkhanud, P. B., Damdinsuren, B., Bodogai, M., Gress, R. E., Sen, R., Wejksza, K., Malchinkhuu, E., Wersto, R. P., & Biragyn, A. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-4316 · Cited by 689 · see citing works

PDL1 Regulation by p53 via miR-34

Cortez, M. A., Ivan, C., Valdecanas, D., Wang, X., Peltier, H. J., Ye, Y., Araujo, L., Carbone, D. P., Shilo, K., Giri, D. K., et al. (2016) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djv303 · Cited by 683 · see citing works

Coexpression of Tim-3 and PD-1 identifies a CD8+ T-cell exhaustion phenotype in mice with disseminated acute myelogenous leukemia

Zhou, Q., Munger, M. E., Veenstra, R. G., Weigel, B. J., Hirashima, M., Munn, D. H., Murphy, W. J., Azuma, M., Anderson, A. C., Kuchroo, V. K., et al. (2011) · Blood · doi:10.1182/blood-2010-10-310425 · Cited by 675 · see citing works

Tumor cell expression of programmed cell death‐1 ligand 1 is a prognostic factor for malignant melanoma

Hino, R., Kabashima, K., Kato, Y., Yagi, H., Nakamura, M., Honjo, T., Okazaki, T., & TOKURA, Y. (2010) · Cancer · doi:10.1002/cncr.24899 · Cited by 668 · see citing works

Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients

Hodi, F. S., Butler, M., Oble, D. A., Seiden, M. V., Haluska, F. G., Kruse, A., MacRae, S., Nelson, M., Canning, C., Lowy, I., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0712237105 · Cited by 650 · see citing works

Current Diagnosis and Management of Immune Related Adverse Events (irAEs) Induced by Immune Checkpoint Inhibitor Therapy

Kumar, V., Chaudhary, N., Garg, M., Floudas, C. S., Soni, P., & Chandra, A. B. (2017) · Frontiers in Pharmacology · doi:10.3389/fphar.2017.00049 · Cited by 631 · see citing works

Immune Therapy for Cancer

Dougan, M. L., & Dranoff, G. (2008) · Annual Review of Immunology · doi:10.1146/annurev.immunol.021908.132544 · Cited by 610 · see citing works

Myeloid-Derived Suppressor Cells Suppress Antitumor Immune Responses through IDO Expression and Correlate with Lymph Node Metastasis in Patients with Breast Cancer

Yu, J., Du, W., Fang, Y., Wang, Y., Li, H., Cao, S., Yu, W., Shen, C., Liu, J., & Ren, X. (2013) · The Journal of Immunology · doi:10.4049/jimmunol.1201449 · Cited by 608 · see citing works

Avelumab in metastatic urothelial carcinoma after platinum failure (JAVELIN Solid Tumor): pooled results from two expansion cohorts of an open-label, phase 1 trial

Patel, M. R., Ellerton, J., Infante, J. R., Agrawal, M., Gordon, M., Aljumaily, R., Britten, C. D., Dirix, L., Lee, K.-W., Taylor, M., et al. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30900-2 · Cited by 590 · see citing works

Molecular regulation of effector and memory T cell differentiation

Chang, J. T., Wherry, E. J., & Goldrath, A. W. (2014) · Nature Immunology · doi:10.1038/ni.3031 · Cited by 578 · see citing works

Class IIa HDAC inhibition reduces breast tumours and metastases through anti-tumour macrophages

Guerriero, J. L., Sotayo, A., Ponichtera, H. E., Castrillon, J. A., Pourzia, A. L., Schad, S., Johnson, S. F., Carrasco, R. D., Lazo, S., Bronson, R. T., et al. (2017) · Nature · doi:10.1038/nature21409 · Cited by 558 · see citing works

Metabolic Regulation of T Cell Longevity and Function in Tumor Immunotherapy

Kishton, R. J., Sukumar, M., & Restifo, N. P. (2017) · Cell Metabolism · doi:10.1016/j.cmet.2017.06.016 · Cited by 548 · see citing works

Clinical Challenges of Immune Checkpoint Inhibitors

Miguel, M. J. D., & Calvo, E. (2020) · Cancer Cell · doi:10.1016/j.ccell.2020.07.004 · Cited by 542 · see citing works

Myeloid-Derived Suppressor Cells Hinder the Anti-Cancer Activity of Immune Checkpoint Inhibitors

Weber, R., Fleming, V., Hu, X., Nagibin, V. S., Groth, C., Altevogt, P., Utikal, J. S., & Umansky, V. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.01310 · Cited by 535 · see citing works

Galectin-3 Shapes Antitumor Immune Responses by Suppressing CD8+ T Cells via LAG-3 and Inhibiting Expansion of Plasmacytoid Dendritic Cells

Kouo, T., Huang, L., Pucsek, A. B., Cao, M., Solt, S., Armstrong, T., & Jaffee, E. (2015) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-14-0150 · Cited by 531 · see citing works

Macrophage polarity in cancer: A review

Najafi, M., Goradel, N. H., Farhood, B., Salehi, E., Nashtaei, M. S., Khanlarkhani, N., Khezri, Z., Majidpoor, J., Abouzaripour, M., Habibi, M., et al. (2018) · Journal of Cellular Biochemistry · doi:10.1002/jcb.27646 · Cited by 491 · see citing works

TIM-3 Expression Characterizes Regulatory T Cells in Tumor Tissues and Is Associated with Lung Cancer Progression

Gao, X., Zhu, Y., Li, G., Huang, H., Zhang, G., Fengming, W., Sun, J., Yang, Q., Zhang, X., & Lu, B. (2012) · PLoS ONE · doi:10.1371/journal.pone.0030676 · Cited by 406 · see citing works

TIM-3 regulates CD103+ dendritic cell function and response to chemotherapy in breast cancer

de Mingo Pulido, Á., Gardner, A., Hiebler, S., Soliman, H., Rugo, H. S., Krummel, M. F., Coussens, L. M., & Ruffell, B. (2018) · Cancer Cell · doi:10.1016/j.ccell.2017.11.019 · Cited by 388 · see citing works

Immune-checkpoint proteins VISTA and PD-1 nonredundantly regulate murine T-cell responses

Liu, J., Yuan, Y., Chen, W., Putra, J., Suriawinata, A. A., Schenk, A. D., Miller, H. E., Guleria, I., Barth, R. J., Huang, Y. H., et al. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1420370112 · Cited by 374 · see citing works

PD-1hi identifies a novel regulatory b-cell population in human hepatoma that promotes disease progression

Xiao, X., Lao, X.-M., Chen, M.-M., Liu, R.-X., Wei, Y., Ouyang, F.-Z., Chen, D.-P., Zhao, X.-Y., Zhao, Q., Li, X.-F., et al. (2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-1408 · Cited by 352 · see citing works

Myeloid cells are required for PD-1/PD-L1 checkpoint activation and the establishment of an immunosuppressive environment in pancreatic cancer

Zhang, Y., Velez-Delgado, A., Mathew, E., Li, D., Mendez, F., Flannagan, K., Rhim, A. D., Simeone, D. M., Beatty, G. L., & di Magliano, M. P. (2016) · Gut · doi:10.1136/gutjnl-2016-312078 · Cited by 338 · see citing works

Blocking expression of inhibitory receptor NKG2A overcomes tumor resistance to NK cells

Kamiya, T., Seow, S. V., Wong, D., Robinson, M., & Campana, D. (2019) · Journal of Clinical Investigation · doi:10.1172/jci123955 · Cited by 337 · see citing works

TIM3+FOXP3+regulatory T cells are tissue-specific promoters of T-cell dysfunction in cancer

Sakuishi, K., Ngiow, S. F., Sullivan, J. M., Teng, M. W. L., Kuchroo, V. K., Smyth, M. J., & Anderson, A. C. (2013) · OncoImmunology · doi:10.4161/onci.23849 · Cited by 329 · see citing works

Inhibition of the B7-H3 immune checkpoint limits tumor growth by enhancing cytotoxic lymphocyte function

Lee, Y.-H., Martin-Orozco, N., Zheng, P., Li, J., Zhang, P., Tan, H., Park, H. J., Jeong, M., Chang, S. H., Kim, B.-S., et al. (2017) · Cell Research · doi:10.1038/cr.2017.90 · Cited by 328 · see citing works

Tumor suppressor miR-34a targets PD-L1 and functions as a potential immunotherapeutic target in acute myeloid leukemia

Wang, X., Li, J., Dong, K., Fang, L., Long, M., Ouyang, Y., Wei, J., Chen, X., Weng, Y., He, T., et al. (2014) · Cellular Signalling · doi:10.1016/j.cellsig.2014.12.003 · Cited by 313 · see citing works

Prognostic effect of different PD-L1 expression patterns in squamous cell carcinoma and adenocarcinoma of the cervix

Heeren, A. M., Punt, S., Bleeker, M. C. G., Gaarenstroom, K. N., van der Velden, J., Kenter, G. G., de Gruijl, T. D., & Jordanova, E. S. (2016) · Modern Pathology · doi:10.1038/modpathol.2016.64 · Cited by 309 · see citing works

Treating cancer with microRNA replacement therapy: A literature review

Hosseinahli, N., Aghapour, M., Duijf, P. H. G., & Baradaran, B. (2018) · Journal of Cellular Physiology · doi:10.1002/jcp.26514 · Cited by 307 · see citing works

TIGIT immune checkpoint blockade restores CD8+ T-cell immunity against multiple myeloma

Guillerey, C., Harjunpää, H., Carrié, N., Kassem, S., Teo, T., Miles, K., Krumeich, S., Weulersse, M., Cuisinier, M., Stannard, K., et al. (2018) · Blood · doi:10.1182/blood-2018-01-825265 · Cited by 300 · see citing works

BTLA mediates inhibition of human tumor-specific CD8+ T cells that can be partially reversed by vaccination

Derré, L., Rivals, J.-P., Jandus, C., Pastor, S., Rimoldi, D., Romero, P., Michielin, O., Olive, D., & Speiser, D. E. (2010) · Journal of Clinical Investigation · doi:10.1172/jci40070 · Cited by 295 · see citing works

miR-424(322) reverses chemoresistance via T-cell immune response activation by blocking the PD-L1 immune checkpoint

Xu, S., Tao, Z., Hai, B., Liang, H., Shi, Y. Q., Wang, T., Song, W., Chen, Y., Ouyang, J., Chen, J., et al. (2016) · Nature Communications · doi:10.1038/ncomms11406 · Cited by 290 · see citing works

CTLA-4 Blockade Synergizes Therapeutically with PARP Inhibition in BRCA1-Deficient Ovarian Cancer

Higuchi, T., Flies, D. B., Marjon, N. A., Mantia-Smaldone, G. M., Ronner, L., Gimotty, P. A., & Adams, S. F. (2015) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-15-0044 · Cited by 286 · see citing works

PD-1 Blockade by CT-011, Anti-PD-1 Antibody, Enhances Ex Vivo T-cell Responses to Autologous Dendritic Cell/Myeloma Fusion Vaccine

Rosenblatt, J. M., Glotzbecker, B. E., Mills, H., Vasir, B., Tzachanis, D., Levine, J. D., Joyce, R., Wellenstein, K., Keefe, W., Schickler, M., et al. (2011) · Journal of Immunotherapy · doi:10.1097/cji.0b013e31821ca6ce · Cited by 284 · see citing works

PD1 blockade reverses the suppression of melanoma antigen-specific CTL by CD4+CD25Hi regulatory T cells

Wang, W., Lau, R., Yu, D., Zhu, W., Korman, A. J., & Weber, J. S. (2009) · International Immunology · doi:10.1093/intimm/dxp072 · Cited by 277 · see citing works

A phase 1 trial of the anti-inhibitory KIR mAb IPH2101 for AML in complete remission

Vey, N., Bourhis, J.-H., Boissel, N., Bordessoule, D., Prébet, T., Charbonnier, A., Etienne, A., André, P., Romagné, F., Benson, D., et al. (2012) · Blood · doi:10.1182/blood-2012-06-437558 · Cited by 277 · see citing works

CTLA-4+ Regulatory T Cells Increased in Cetuximab-Treated Head and Neck Cancer Patients Suppress NK Cell Cytotoxicity and Correlate with Poor Prognosis

Jie, H.-B., Schuler, P. J., Lee, S. C., Srivastava, R. M., Argiris, A. E., Ferrone, S., Whiteside, T. L., & Ferris, R. L. (2015) · Cancer Research · doi:10.1158/0008-5472.can-14-2788 · Cited by 267 · see citing works

Mouse TIGIT inhibits NK ‐cell cytotoxicity upon interaction with PVR

Stanietsky, N., Roviš, T. L., Glasner, A., Seidel, E., Tsukerman, P., Yamin, R., Enk, J., Jonjić, S., & Mandelboim, O. (2013) · European Journal of Immunology · doi:10.1002/eji.201243072 · Cited by 265 · see citing works

Divergent Phenotypes of Human Regulatory T Cells Expressing the Receptors TIGIT and CD226

Fuhrman, C. A., Yeh, W.-I., Seay, H. R., Lakshmi, P. S., Chopra, G., Zhang, L., Perry, D. J., McClymont, S., Yadav, M., Lopez, M.-C., et al. (2015) · The Journal of Immunology · doi:10.4049/jimmunol.1402381 · Cited by 262 · see citing works

The Clinical Relevance of the miR-197/CKS1B/STAT3-mediated PD-L1 Network in Chemoresistant Non-small-cell Lung Cancer

Fujita, Y., Yagishita, S., Hagiwara, K., Yoshioka, Y., Kosaka, N., Takeshita, F., Fujiwara, T., Tsuta, K., Nokihara, H., Tamura, T., et al. (2015) · Molecular Therapy · doi:10.1038/mt.2015.10 · Cited by 262 · see citing works

PD-1 restraint of regulatory T cell suppressive activity is critical for immune tolerance

Tan, C. L., Kuchroo, J. R., Sage, P. T., Liang, D., Francisco, L. M., Buck, J. N., Thaker, Y. R., Zhang, Q., McArdel, S. L., Juneja, V. R., et al. (2020) · The Journal of Experimental Medicine · doi:10.1084/jem.20182232 · Cited by 252 · see citing works

Modulation of Lymphocyte Regulation for Cancer Therapy: A Phase II Trial of Tremelimumab in Advanced Gastric and Esophageal Adenocarcinoma

Ralph, C., Elkord, E., Burt, D. J., O'Dwyer, J. F., Austin, E. B., Stern, P. L., Hawkins, R. E., & Thistlethwaite, F. C. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-2870 · Cited by 250 · see citing works

Treg-mediated acquired resistance to immune checkpoint inhibitors

Saleh, R., & Elkord, E. (2019) · Cancer Letters · doi:10.1016/j.canlet.2019.05.003 · Cited by 238 · see citing works

Triple negative breast cancer: Key role of Tumor-Associated Macrophages in regulating the activity of anti-PD-1/PD-L1 agents

Santoni, M., Romagnoli, E., Saladino, T., Foghini, L., Guarino, S., Capponi, M., Giannini, M., Cognigni, P. D., Ferrara, G., & Battelli, N. (2017) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2017.10.007 · Cited by 238 · see citing works

The tumor suppressor miR-138-5p targets PD-L1 in colorectal cancer

Zhao, L., Yu, H., Yi, S., Peng, X., Su, P., Xiao, Z., Liu, R., Tang, A., Li, X., Liu, F., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.9659 · Cited by 227 · see citing works

Hypoxia-Induced VISTA Promotes the Suppressive Function of Myeloid-Derived Suppressor Cells in the Tumor Microenvironment

Deng, J., Li, J., Sarde, A., Lines, J. L., Lee, Y.-C., Qian, D. C., Pechenick, D. A., Manivanh, R., Le Mercier, I., Lowrey, C. H., et al. (2019) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-18-0507 · Cited by 224 · see citing works

Blockade of TIGIT/CD155 Signaling Reverses T-cell Exhaustion and Enhances Antitumor Capability in Head and Neck Squamous Cell Carcinoma

Wu, L., Mao, L., Liu, J., Chen, L., Yu, G., Yang, L., Wu, H., Bu, L., Kulkarni, A. B., Zhang, W., et al. (2019) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-18-0725 · Cited by 219 · see citing works

Increased Tim-3 expression in peripheral NK cells predicts a poorer prognosis and Tim-3 blockade improves NK cell-mediated cytotoxicity in human lung adenocarcinoma

Xu, L., Huang, Y., Tan, L., Yu, W., Chen, D., Lu, C., He, J.-Y., Wu, G., Liu, X., & Zhang, Y. (2015) · International Immunopharmacology · doi:10.1016/j.intimp.2015.09.017 · Cited by 215 · see citing works

Regulatory T cells: a potential target in cancer immunotherapy

Shitara, K., & Nishikawa, H. (2018) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.13625 · Cited by 215 · see citing works

VISTA expressed in tumour cells regulates T cell function

Mulati, K., Hamanishi, J., Matsumura, N., Chamoto, K., Mise, N., Abiko, K., Baba, T., Yamaguchi, K. D., Horikawa, N., Murakami, R., et al. (2018) · British Journal of Cancer · doi:10.1038/s41416-018-0313-5 · Cited by 208 · see citing works

Not all immune-checkpoint inhibitors are created equal: Meta-analysis and systematic review of immune-related adverse events in cancer trials

Osta, B. E. E., Hu, F., Sadek, R. A., Chintalapally, R., & Tang, S. C. (2017) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2017.09.002 · Cited by 207 · see citing works

Inhibitory Receptors and Pathways of Lymphocytes: The Role of PD-1 in Treg Development and Their Involvement in Autoimmunity Onset and Cancer Progression

Gianchecchi, E., & Fierabracci, A. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.02374 · Cited by 207 · see citing works

Combination immunotherapy with α-CTLA-4 and α-PD-L1 antibody blockade prevents immune escape and leads to complete control of metastatic osteosarcoma

Lussier, D. M., Johnson, J. L., Hingorani, P., & Blattman, J. N. (2015) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-015-0067-z · Cited by 206 · see citing works

MiR-138 exerts anti-glioma efficacy by targeting immune checkpoints

Wei, J., Nduom, E. K.-E., Kong, L.-Y., Hashimoto, Y., Xu, S., Gabrusiewicz, K. R., Ling, X., Huang, N., Qiao, W., Zhou, S., et al. (2015) · Neuro-Oncology · doi:10.1093/neuonc/nov292 · Cited by 199 · see citing works

Adaptive NK Cells with Low TIGIT Expression Are Inherently Resistant to Myeloid-Derived Suppressor Cells

Sarhan, D., Cichocki, F. M., Zhang, B., Yingst, A. M., Spellman, S. R., Cooley, S., Verneris, M. R., Blazar, B. R., & Miller, J. S. (2016) · Cancer Research · doi:10.1158/0008-5472.can-16-0839 · Cited by 198 · see citing works

Immune-Checkpoint Protein VISTA Regulates Antitumor Immunity by Controlling Myeloid Cell–Mediated Inflammation and Immunosuppression

Xu, W., Dong, J., Zheng, Y., Zhou, J., Yuan, Y., Ta, H. M., Miller, H. E., Olson, M., Rajasekaran, K., Ernstoff, M. S., et al. (2019) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-18-0489 · Cited by 190 · see citing works

B7-H4(B7x)–Mediated Cross-talk between Glioma-Initiating Cells and Macrophages via the IL6/JAK/STAT3 Pathway Lead to Poor Prognosis in Glioma Patients

Yao, Y., Ye, H., Qi, Z., Mo, L., Qi, Y., Baral, A., Hoon, D. S. �., Vera, J. C., Heiss, J. D., Chen, C. C., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-0858 · Cited by 188 · see citing works

Tumor Suppressive MicroRNAs miR-34a/c Control Cancer Cell Expression of ULBP2, a Stress-Induced Ligand of the Natural Killer Cell Receptor NKG2D

Heinemann, A., Zhao, F., Pechlivanis, S., Eberle, J., Steinle, A., Diederichs, S., Schadendorf, D., & Paschen, A. (2011) · Cancer Research · doi:10.1158/0008-5472.can-11-1977 · Cited by 187 · see citing works

Rapid development of exhaustion and down-regulation of eomesodermin limit the antitumor activity of adoptively transferred murine natural killer cells

Gill, S. I., Vasey, A. E., Souza, A. D., Baker, J. B., Smith, A. T., Kohrt, H. E. K., Florek, M., Gibbs, K. D., Tate, K. M., Ritchie, D. S., et al. (2012) · Blood · doi:10.1182/blood-2012-03-415364 · Cited by 183 · see citing works

Tim-3 Expression Defines Regulatory T Cells in Human Tumors

Yan, J., Zhang, Y., Zhang, J., Liang, J., Li, L., & Zheng, L. (2013) · PLoS ONE · doi:10.1371/journal.pone.0058006 · Cited by 183 · see citing works

Combined PD-1 blockade and GITR triggering induce a potent antitumor immunity in murine cancer models and synergizes with chemotherapeutic drugs

Lü, L., Xu, X., Zhang, B., Zhang, R., Ji, H., & Wang, X. (2014) · Journal of Translational Medicine · doi:10.1186/1479-5876-12-36 · Cited by 179 · see citing works

Blockade of adenosine A2A receptor enhances CD8+ T cells response and decreases regulatory T cells in head and neck squamous cell carcinoma

Ma, S., Deng, W., Liu, J., Mao, L., Yu, G., Bu, L., Kulkarni, A. B., Zhang, W., & Sun, Z. (2017) · Molecular Cancer · doi:10.1186/s12943-017-0665-0 · Cited by 179 · see citing works

VISTA is highly expressed on MDSCs and mediates an inhibition of T cell response in patients with AML

Wang, L., Jia, B., Claxton, D. F., Ehmann, W. C., Rybka, W. B., Mineishi, S., Naik, S. G., Khawaja, M. R., Sivik, J., Han, J., et al. (2018) · OncoImmunology · doi:10.1080/2162402x.2018.1469594 · Cited by 179 · see citing works

α-PD-1 therapy elevates Treg/Th balance and increases tumor cell pSmad3 that are both targeted by α-TGFβ antibody to promote durable rejection and immunity in squamous cell carcinomas

Dodagatta-Marri, E., Meyer, D. S., Reeves, M. Q., Paniagua, R., To, M. D., Binnewies, M., Broz, M. L., Mori, H., Wu, D., Adoumie, M., et al. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-018-0493-9 · Cited by 177 · see citing works

Targeting LAG-3 and PD-1 to Enhance T Cell Activation by Antigen-Presenting Cells

Lichtenegger, F. S., Rothe, M., Schnorfeil, F. M., Deiser, K., Krupka, C., Augsberger, C., Schlüter, M., Neitz, J. S., & Subklewe, M. S. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.00385 · Cited by 176 · see citing works

CTLA-4 Is Expressed by Activated Mouse NK Cells and Inhibits NK Cell IFN-γ Production in Response to Mature Dendritic Cells

Stojanovic, A., Fiegler, N., Brunner-Weinzierl, M. C., & Cerwenka, A. (2014) · The Journal of Immunology · doi:10.4049/jimmunol.1302091 · Cited by 175 · see citing works

PSGL-1 Is an Immune Checkpoint Regulator that Promotes T Cell Exhaustion

Tinoco, R., Carrette, F., Henriquez, M. L., Otero, D. C., Magaña, J., Bosenberg, M., Swain, S. L., & Bradley, L. M. (2016) · Immunity · doi:10.1016/j.immuni.2016.04.015 · Cited by 174 · see citing works

Phase I study combining anti-PD-L1 (MEDI4736) with BRAF (dabrafenib) and/or MEK (trametinib) inhibitors in advanced melanoma.

Ribas, A., Butler, M. O., Lutzky, J., Lawrence, D. P., Robert, C., Miller, W. H., Linette, G. P., Ascierto, P. A., Kuzel, T. M., Algazi, A. P., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.33.15_suppl.3003 · Cited by 158 · see citing works

PSGL-1: A New Player in the Immune Checkpoint Landscape

Tinoco, R., Otero, D. C., Takahashi, A. A., & Bradley, L. M. (2017) · Trends in Immunology · doi:10.1016/j.it.2017.02.002 · Cited by 155 · see citing works

Blockade of CD112R and TIGIT signaling sensitizes human natural killer cell functions

Xu, F., Sunderland, A., Zhou, Y., Schulick, R. D., Edil, B. H., & Zhu, Y. (2017) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-017-2031-x · Cited by 152 · see citing works

Immune checkpoint inhibitors in cancer therapy

Eika, S., Peng, L., Baleeiro, R. B., Nicholas, R., Ming, Y., & Yaohe, W. (2017) · Journal of Biomedical Research · doi:10.7555/jbr.31.20160168 · Cited by 150 · see citing works

Inhibition of natural killer cell activation signals by killer cell immunoglobulin‐like receptors (CD158)

Long, E. O., Barber, D. F., Burshtyn, D. N., Faure, M., Peterson, M., Rajagopalan, S., Renard, V., Sandusky, M., Stebbins, C. C., Wagtmann, N. R., et al. (2001) · Immunological Reviews · doi:10.1034/j.1600-065x.2001.1810119.x · Cited by 146 · see citing works

Tumor-Promoting Effects of Myeloid-Derived Suppressor Cells Are Potentiated by Hypoxia-Induced Expression of miR-210

Noman, M. Z., Janji, B., Hu, S., Wu, J. C., Martelli, F., Bronte, V., & Chouaı̈b, S. (2015) · Cancer Research · doi:10.1158/0008-5472.can-15-0405 · Cited by 144 · see citing works

Therapeutic CD94/NKG2A blockade improves natural killer cell dysfunction in chronic lymphocytic leukemia

McWilliams, E. M., Mele, J. M., Cheney, C. M., Timmerman, E. A., Fiazuddin, F., Strattan, E., Mo, X. M., Byrd, J. C., Muthusamy, N., & Awan, F. T. (2016) · OncoImmunology · doi:10.1080/2162402x.2016.1226720 · Cited by 144 · see citing works

PD-1-expressing B cells suppress CD4+ and CD8+ T cells via PD-1/PD-L1-dependent pathway

Wang, X., Wang, G., Wang, Z., Liu, B., Han, N., Li, J., Lu, C., Liu, X., Zhang, Q., Yang, Q., et al. (2019) · Molecular Immunology · doi:10.1016/j.molimm.2019.02.009 · Cited by 142 · see citing works

Phenformin Inhibits Myeloid-Derived Suppressor Cells and Enhances the Anti-Tumor Activity of PD-1 Blockade in Melanoma

Kim, S. H., Li, M., Trousil, S., Zhang, Y., di Magliano, M. P., Swanson, K. D., & Zheng, B. (2017) · Journal of Investigative Dermatology · doi:10.1016/j.jid.2017.03.033 · Cited by 140 · see citing works

Immunosuppressive networks and checkpoints controlling antitumor immunity and their blockade in the development of cancer immunotherapeutics and vaccines

Butt, A., & Mills, K. H. G. (2013) · Oncogene · doi:10.1038/onc.2013.432 · Cited by 139 · see citing works

PD-1H (VISTA)–mediated suppression of autoimmunity in systemic and cutaneous lupus erythematosus

Han, X. N., Vesely, M. D., Yang, W., Sanmamed, M. F., Badri, T., Alawa, J., López‐Giráldez, F., Gaule, P., Lee, S. W., Zhang, J., et al. (2019) · Science Translational Medicine · doi:10.1126/scitranslmed.aax1159 · Cited by 139 · see citing works

Differential contribution of three immune checkpoint (VISTA, CTLA-4, PD-1) pathways to antitumor responses against squamous cell carcinoma

Kondo, Y., Ohno, T., Nishii, N., Harada, K., Yagita∥, H., & Azuma, M. (2016) · Oral Oncology · doi:10.1016/j.oraloncology.2016.04.005 · Cited by 137 · see citing works

Tumor-expressed B7-H3 mediates the inhibition of antitumor T-cell functions in ovarian cancer insensitive to PD-1 blockade therapy

Cai, D., Li, J., Liu, D., Hong, S., Qiao, Q., Sun, Q., Li, P., Lyu, N., Sun, T., Xie, S., et al. (2019) · Cellular and Molecular Immunology · doi:10.1038/s41423-019-0305-2 · Cited by 133 · see citing works

miR-28 modulates exhaustive differentiation of T cells through silencing programmed cell death-1 and regulating cytokine secretion

Li, Q., Johnston, N., Zheng, X., Wang, H., Zhang, X., Gao, D., & Min, W. (2016) · Oncotarget · doi:10.18632/oncotarget.10731 · Cited by 132 · see citing works

PD-1 and BTLA regulate T cell signaling differentially and only partially through SHP1 and SHP2

Xu, X., Hou, B., Fulzele, A., Masubuchi, T., Zhao, Y., Wu, Z., Hu, Y., Jiang, Y., Ma, Y., Wang, H., et al. (2020) · The Journal of Cell Biology · doi:10.1083/jcb.201905085 · Cited by 131 · see citing works

Mature natural killer cells with phenotypic and functional alterations accumulate upon sustained stimulation with IL-15/IL-15Rα complexes

Elpek, K. G., Rubinstein, M. P., Bellemare-Pelletier, A., Goldrath, A. W., & Turley, S. J. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1012128107 · Cited by 130 · see citing works

Blockade of TIM3 relieves immunosuppression through reducing regulatory T cells in head and neck cancer

Liu, J., Wu, L., Yang, L., Deng, W., Mao, L., Wu, H., Zhang, W., & Sun, Z. (2018) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-018-0713-7 · Cited by 127 · see citing works

T-Cell Therapy Using Interleukin-21–Primed Cytotoxic T-Cell Lymphocytes Combined With Cytotoxic T-Cell Lymphocyte Antigen-4 Blockade Results in Long-Term Cell Persistence and Durable Tumor Regression

Chapuis, A. G., Roberts, I. M., Thompson, J. A., Margolin, K. A., Bhatia, S., Lee, S. M., Sloan, H. L., Lai, I. P., Farrar, E. A., Wagener, F. D., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.65.5142 · Cited by 122 · see citing works

Mammary-tumor-educated B cells acquire LAP/TGF-β and PD-L1 expression and suppress anti-tumor immune responses

Zhang, Y. X., Morgan, R., Chen, C., Cai, Y., Clark, E., Khan, W. N., Shin, S.-U., Cho, H.-M., Bayati, A. A., Pimentel, A., et al. (2016) · International Immunology · doi:10.1093/intimm/dxw007 · Cited by 118 · see citing works

Immune checkpoint blockade opens a new way to cancer immunotherapy

Sadreddini, S., Baradaran, B., Aghebati‐Maleki, A., Sadreddini, S., Shanehbandi, D., Fotouhi, A., & Maleki, L. A. (2018) · Journal of Cellular Physiology · doi:10.1002/jcp.27816 · Cited by 118 · see citing works

MicroRNA-187, down-regulated in clear cell renal cell carcinoma and associated with lower survival, inhibits cell growth and migration though targeting B7-H3

Zhao, J. Y., Lei, T., Xu, C., Li, H., Ma, W., Yang, Y., Fan, S., & Liu, Y. (2013) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2013.07.095 · Cited by 116 · see citing works

The immune checkpoint protein PD-L1 induces and maintains regulatory T cells in glioblastoma

DiDomenico, J. D., Lamano, J. B., Oyon, D. E., Li, Y., Veliceasa, D., Kaur, G., Ampie, L., Choy, W., Lamano, J. B., & Bloch, O. G. (2018) · OncoImmunology · doi:10.1080/2162402x.2018.1448329 · Cited by 115 · see citing works

CAR-T “the living drugs”, immune checkpoint inhibitors, and precision medicine: a new era of cancer therapy

Liu, D. (2019) · Journal of Hematology & Oncology · doi:10.1186/s13045-019-0819-1 · Cited by 108 · see citing works

Tim-3 promotes tumor-promoting M2 macrophage polarization by binding to STAT1 and suppressing the STAT1-miR-155 signaling axis

Jiang, X., Zhou, T., Xiao, Y., Yu, J., Dou, S., Chen, G., Wang, R., He, X., Hou, C., Wang, W., et al. (2016) · OncoImmunology · doi:10.1080/2162402x.2016.1211219 · Cited by 106 · see citing works

PD-1 and LAG-3 Dominate Checkpoint Receptor–Mediated T-cell Inhibition in Renal Cell Carcinoma

Zelba, H., Bedke, J., Hennenlotter, J., Mostböck, S., Zettl, M., Zichner, T., Chandran, A., Stenzl, A., Rammensee, H., & Gouttefangeas, C. (2019) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-19-0146 · Cited by 105 · see citing works

SDF-1/CXCR4 axis facilitates myeloid-derived suppressor cells accumulation in osteosarcoma microenvironment and blunts the response to anti-PD-1 therapy

Jiang, K., Li, J., Zhang, J., Wang, L., Zhang, Q., Ge, J., Guo, Y., Wang, B., Huang, Y., Yang, T., et al. (2019) · International Immunopharmacology · doi:10.1016/j.intimp.2019.105818 · Cited by 105 · see citing works

A novel MDSC-induced PD-1 − PD-L1 + B-cell subset in breast tumor microenvironment possesses immuno-suppressive properties

Shen, M., Wang, J., Yu, W., Zhang, C., Liu, M., Wang, K., Yang, L., Wei, F., Wang, S. E., Sun, Q., et al. (2017) · OncoImmunology · doi:10.1080/2162402x.2017.1413520 · Cited by 103 · see citing works

The role of PD-1/PD-L1 axis and macrophage in the progression and treatment of cancer

Cai, J., Qi, Q., Qian, X., Han, J. G., Zhu, X., Zhang, Q., & Xia, R. (2019) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-019-02879-2 · Cited by 101 · see citing works

Non-small Cell Lung Cancer Induces an Immunosuppressive Phenotype of Dendritic Cells in Tumor Microenvironment by Upregulating B7-H3

Schneider, T., Hoffmann, H., Dienemann, H., Schnabel, P. A., Enk, A., Ring, S., & Mahnke, K. (2011) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e31821c421d · Cited by 98 · see citing works

MicroRNA Profile of Circulating CD4-positive Regulatory T Cells in Human Adults and Impact of Differentially Expressed MicroRNAs on Expression of Two Genes Essential to Their Function

Fayyad‐Kazan, H., Rouas, R., Fayyad‐Kazan, M., Badran, R., Zein, N. E., Lewalle, P., Najar, M., Hamade, E., Jebbawi, F., Merimi, M., et al. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.337154 · Cited by 97 · see citing works

MiR-195/-16 Family Enhances Radiotherapy via T Cell Activation in the Tumor Microenvironment by Blocking the PD-L1 Immune Checkpoint

Tao, Z., Xu, S., Ruan, H., Wang, T., Song, W., Li, Q., & Chen, K. (2018) · Cellular Physiology and Biochemistry · doi:10.1159/000491909 · Cited by 91 · see citing works

Tumor-infiltrating regulatory T cells delineated by upregulation of PD-1 and inhibitory receptors

Park, H., Kusnadi, A., Lee, E., Kim, W. W., Cho, B. C., Lee, I. J., Seong, J., & Ha, S. (2012) · Cellular Immunology · doi:10.1016/j.cellimm.2012.07.001 · Cited by 90 · see citing works

Manipulating both the inhibitory and stimulatory immune system towards the success of therapeutic vaccination against chronic viral infections

Ha, S., West, E. E., Araki, K., Smith, K. A., & Ahmed, R. (2008) · Immunological Reviews · doi:10.1111/j.1600-065x.2008.00638.x · Cited by 90 · see citing works

IFNAR1 Controls Autocrine Type I IFN Regulation of PD-L1 Expression in Myeloid-Derived Suppressor Cells

Xiao, W. L., Klement, J. D., Lu, C., Ibrahim, M. L., & Liu, K. (2018) · The Journal of Immunology · doi:10.4049/jimmunol.1800129 · Cited by 89 · see citing works

Hepatocellular carcinoma-derived high mobility group box 1 triggers M2 macrophage polarization via a TLR2/NOX2/autophagy axis

Shiau, D.-J., Kuo, W., Davuluri, G. V. N., Shieh, C.-C. K., Tsai, P.-J., Chen, C., Lin, Y.-S., Wu, Y.-Z., Hsiao, Y.-P., & Chang, C. (2020) · Scientific Reports · doi:10.1038/s41598-020-70137-4 · Cited by 89 · see citing works

Activation of NK cells and disruption of PD-L1/PD-1 axis: two different ways for lenalidomide to block myeloma progression

Giuliani, M., Janji, B., & Berchem, G. (2017) · Oncotarget · doi:10.18632/oncotarget.15234 · Cited by 88 · see citing works

Tryptophan Catabolism and Cancer Immunotherapy Targeting IDO Mediated Immune Suppression

Amobi, A. E., Qian, F., Lugade, A. A., & Odunsi, K. O. (2017) · Advances in experimental medicine and biology · doi:10.1007/978-3-319-67577-0_9 · Cited by 88 · see citing works

Pancreatic Cancer Signaling Pathways, Genetic Alterations, and Tumor Microenvironment: The Barriers Affecting the Method of Treatment

Javadrashid, D., Baghbanzadeh, A., Derakhshani, A., Leone, P., Silvestris, N., Racanelli, V., Solimando, A. G., & Baradaran, B. (2021) · Biomedicines · doi:10.3390/biomedicines9040373 · Cited by 87 · see citing works

Cytotoxic T-Lymphocyte Antigen-4 in Colorectal Cancer: Another Therapeutic Side of Capecitabine

Derakhshani, A., Hashemzadeh, S., Asadzadeh, Z., Shadbad, M. A., Rasibonab, F., Safarpour, H., Jafarlou, V., Solimando, A. G., Racanelli, V., Singh, P., et al. (2021) · Cancers · doi:10.3390/cancers13102414 · Cited by 80 · see citing works

The Clinical Significance of Abnormal Tim-3 Expression on NK Cells from Patients with Gastric Cancer

Wang, Z., Zhu, J., Gu, H., Yuan, Y., Zhang, B., Zhu, D., Zhou, J., Zhu, Y., & Chen, W. (2015) · Immunological Investigations · doi:10.3109/08820139.2015.1052145 · Cited by 79 · see citing works

MiR‐15a/16 deficiency enhances anti‐tumor immunity of glioma‐infiltrating CD8+ T cells through targeting mTOR

Yang, J., Liu, R., Deng, Y., Qian, J., Lu, Z., Wang, Y., Zhang, D., Luo, F., & Chu, Y. (2017) · International Journal of Cancer · doi:10.1002/ijc.30912 · Cited by 78 · see citing works

Immune-checkpoint inhibitors for combating T-cell dysfunction in cancer

Grywalska, E., Pasiarski, M., Góźdź, S. S., & Roliński, J. (2018) · OncoTargets and Therapy · doi:10.2147/ott.s150817 · Cited by 76 · see citing works

Clinical relevance of miR-mediated HLA-G regulation and the associated immune cell infiltration in renal cell carcinoma

Jasinski‐Bergner, S., Stoehr, R., Bukur, J., Massa, C., Braun, J., Hüttelmaier, S., Spath, V., Wartenberg, R., Legal, W., Taubert, H. W., et al. (2015) · OncoImmunology · doi:10.1080/2162402x.2015.1008805 · Cited by 76 · see citing works

Clinical significance of programmed cell death‐ligand 1 expression and the immune microenvironment at the invasive front of colorectal cancers with high microsatellite instability

Korehisa, S., Oki, E., Iimori, M., Nakaji, Y., Shimokawa, M., Saeki, H., Okano, S., Oda, Y., & Maehara, Y. (2017) · International Journal of Cancer · doi:10.1002/ijc.31107 · Cited by 76 · see citing works

Targeting B7-H3 Immune Checkpoint With Chimeric Antigen Receptor-Engineered Natural Killer Cells Exhibits Potent Cytotoxicity Against Non-Small Cell Lung Cancer

Yang, S., Cao, B., Zhou, G., Zhu, L., Wang, L., Zhang, L., Kwok, H. F., Zhang, Z., & Zhao, Q. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.01089 · Cited by 76 · see citing works

Increased expression of immunosuppressive molecules on intratumoral and circulating regulatory T cells in non-small-cell lung cancer patients.

Wei, T., Zhang, J., Qin, Y., Wu, Y. C., Zhu, L. X., Lu, L., Tang, G., & Shen, Q. (2015) · Europe PMC (PubMed Central) · Cited by 73 · see citing works

PD-1 Blockade Promotes Emerging Checkpoint Inhibitors in Enhancing T Cell Responses to Allogeneic Dendritic Cells

Stecher, C., Battin, C., Leitner, J. M., Zettl, M., Grabmeier‐Pfistershammer, K., Höeller, C., Zlabinger, G. J., & Steinberger, P. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.00572 · Cited by 72 · see citing works

Depleting Tumor-Associated Tregs Via Nanoparticle-Mediated Hyperthermia to Enhance Anti-CTLA-4 Immunotherapy

Chen, H., Luan, X., Paholak, H. J., Burnett, J., Stevers, N. O., Sansanaphongpricha, K., He, M., Chang, A. E., Li, Q., & Sun, D. (2019) · Nanomedicine · doi:10.2217/nnm-2019-0190 · Cited by 71 · see citing works

B7-H3 augments the pro-angiogenic function of tumor-associated macrophages and acts as a novel adjuvant target for triple-negative breast cancer therapy

Cheng, N., Bei, Y., Song, Y., Zhang, W., Xu, L., Zhang, W., Yang, N., Bai, X., Shu, Y., & Shen, P. (2020) · Biochemical Pharmacology · doi:10.1016/j.bcp.2020.114298 · Cited by 71 · see citing works

The silencing of indoleamine 2,3-dioxygenase 1 (IDO1) in dendritic cells by siRNA-loaded lipid nanoparticles enhances cell-based cancer immunotherapy

Endo, R., Nakamura, T., Kawakami, K., Sato, Y., & Harashima, H. (2019) · Scientific Reports · doi:10.1038/s41598-019-47799-w · Cited by 70 · see citing works

Oral squamous cell carcinoma suppressed antitumor immunity through induction of PD-L1 expression on tumor-associated macrophages

Jiang, C., Yuan, F., Wang, J., & Wu, L. (2016) · Immunobiology · doi:10.1016/j.imbio.2016.12.002 · Cited by 69 · see citing works

Interleukin-15 stimulates natural killer cell-mediated killing of both human pancreatic cancer and stellate cells

Audenaerde, J. R. M. V., Waele, J. D., Marcq, E., Loenhout, J. V., Lion, E., den Bergh, J. M. J. V., Jesenofsky, R., Masamune, A., Roeyen, G., Pauwels, P., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.18185 · Cited by 68 · see citing works

Dual PD-1 and CTLA-4 checkpoint blockade promotes antitumor immune responses through CD4(+)Foxp3(-) cell-mediated modulation of CD103(+) dendritic cells

Beavis, P. A., Henderson, M. A., Giuffrida, L., Davenport, A. J., Petley, E. V., House, I. G., Lai, J., Sek, K., Milenkovski, N., John, L. B., et al. (2018) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-18-0291 · Cited by 68 · see citing works

VISTA Deficiency Accelerates the Development of Fatal Murine Lupus Nephritis

Ceeraz, S., Sergent, P. A., Plummer, S. F., Schned, A. R., Pechenick, D. A., Burns, C. M., & Noelle, R. J. (2016) · Arthritis & Rheumatology · doi:10.1002/art.40020 · Cited by 68 · see citing works

Strategies to Improve the Efficacy of Dendritic Cell-Based Immunotherapy for Melanoma

Hargadon, K. M. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01594 · Cited by 68 · see citing works

The Role of V-Domain Ig Suppressor of T Cell Activation (VISTA) in Cancer Therapy: Lessons Learned and the Road Ahead

Hosseinkhani, N., Derakhshani, A., Shadbad, M. A., Argentiero, A., Racanelli, V., Kazemi, T., Mokhtarzadeh, A., Brunetti, O., Silvestris, N., & Baradaran, B. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.676181 · Cited by 68 · see citing works

CD8+ T cells exhaustion induced by myeloid‐derived suppressor cells in myelodysplastic syndromes patients might be through TIM3/Gal‐9 pathway

Tao, J., Han, D., Gao, S., Zhang, W., Yu, H., Liu, P., Fu, R., Li, L., & Shao, Z. (2019) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.14825 · Cited by 66 · see citing works

MicroRNA-152 regulates immune response via targeting B7-H1 in gastric carcinoma

Wang, Y., Wang, D., Xie, G., Yin, Y., Zhao, E., Tao, K., & Li, R. (2017) · Oncotarget · doi:10.18632/oncotarget.15924 · Cited by 64 · see citing works

Indoleamine-2,3-Dioxygenase in Thyroid Cancer Cells Suppresses Natural Killer Cell Function by Inhibiting NKG2D and NKp46 Expression via STAT Signaling Pathways

Park, A., Yang, Y., Lee, Y., Kim, M. S., Park, Y., Jung, H., Kim, T., Lee, H. G., Choi, I., & Yoon, S. R. (2019) · Journal of Clinical Medicine · doi:10.3390/jcm8060842 · Cited by 62 · see citing works

IDO as a drug target for cancer immunotherapy: recent developments in IDO inhibitors discovery

Qian, S., Zhang, M., Chen, Q., He, Y., Wang, W., & Wang, Z. (2016) · RSC Advances · doi:10.1039/c5ra25046c · Cited by 61 · see citing works

Immune checkpoint inhibitors for cancer treatment

Park, J., Kwon, M., & Shin, E. (2016) · Archives of Pharmacal Research · doi:10.1007/s12272-016-0850-5 · Cited by 60 · see citing works

MicroRNA-140 suppresses osteosarcoma tumor growth by enhancing anti-tumor immune response and blocking mTOR signaling

Ji, X., Wang, E., & Tian, F. (2017) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2017.11.120 · Cited by 56 · see citing works

Regulatory T Cells Suppress Natural Killer Cell Immunity in Patients With Human Cervical Carcinoma

Chang, W., Li, C.-H., Chu, L.-H., Huang, P.-S., Sheu, B., & Huang, S. (2015) · International Journal of Gynecological Cancer · doi:10.1097/igc.0000000000000578 · Cited by 56 · see citing works

Immune checkpoints and the regulation of tolerogenicity in dendritic cells: Implications for autoimmunity and immunotherapy

Funes, S. C., de Lara, A. M., Altamirano-Lagos, M. J., Mackern‐Oberti, J. P., Escobar‐Vera, J., & Kalergis, A. M. (2019) · Autoimmunity Reviews · doi:10.1016/j.autrev.2019.02.006 · Cited by 55 · see citing works

Inhibition of IL-18-mediated myeloid derived suppressor cell accumulation enhances anti-PD1 efficacy against osteosarcoma cancer

Guan, Y., Zhang, R., Peng, Z., Dong, D., Wei, G., & Wang, Y. (2017) · Journal of bone oncology · doi:10.1016/j.jbo.2017.10.002 · Cited by 54 · see citing works

Dendritic Cell-Secreted Cytotoxic T-Lymphocyte-Associated Protein-4 Regulates the T-cell Response by Downmodulating Bystander Surface B7

Halpert, M. M., Konduri, V., Liang, D., Chen, Y., Wing, J. B., Paust, S., Levitt, J. M., & Decker, W. K. (2016) · Stem Cells and Development · doi:10.1089/scd.2016.0009 · Cited by 52 · see citing works

Immunomodulatory role for MicroRNAs: Regulation of PD-1/PD-L1 and CTLA-4 immune checkpoints expression

Skafi, N., Fayyad‐Kazan, M., & Badran, B. M. (2020) · Gene · doi:10.1016/j.gene.2020.144888 · Cited by 52 · see citing works

PD-1+ Treg cells: a foe in cancer immunotherapy?

Aksoylar, H., & Boussiotis, V. A. (2020) · Nature Immunology · doi:10.1038/s41590-020-0801-7 · Cited by 51 · see citing works

Concomitant blockade of A2AR and CTLA‐4 by siRNA‐loaded polyethylene glycol‐chitosan‐alginate nanoparticles synergistically enhances antitumor T‐cell responses

Ghasemi‐Chaleshtari, M., Kiaie, S. H., Irandoust, M., Karami, H., Nabi‐Afjadi, M., Ghani, S., Vanda, N. A., Sede, M. J. G., Ahmadi, A., Masjedi, A., et al. (2020) · Journal of Cellular Physiology · doi:10.1002/jcp.29822 · Cited by 49 · see citing works

Immune Checkpoint Inhibitors in Malignancies with Mismatch Repair Deficiency: A Review of the State of the Current Knowledge

Naboush, A., Roman, C. A. J., & Shapira, I. (2017) · Journal of Investigative Medicine · doi:10.1136/jim-2016-000342 · Cited by 47 · see citing works

Role of microRNA-33a in regulating the expression of PD-1 in lung adenocarcinoma

Boldrini, L., Giordano, M., Niccoli, C., Melfi, F. M. A., Lucchi, M., Mussi, A., & Fontanini, G. (2017) · Cancer Cell International · doi:10.1186/s12935-017-0474-y · Cited by 47 · see citing works

BTLA identifies dysfunctional PD-1-expressing CD4+ T cells in human hepatocellular carcinoma

Zhao, Q., Huang, Z., He, M. Y., Gao, Z., & Kuang, D. (2016) · OncoImmunology · doi:10.1080/2162402x.2016.1254855 · Cited by 46 · see citing works

MiR-570 inhibited the cell proliferation and invasion through directly targeting B7-H1 in hepatocellular carcinoma

Guo, W., Tan, W., Liu, S., Huang, X., Lin, J., Liang, R., Su, L., Su, Q., & Wang, C. (2015) · Tumor Biology · doi:10.1007/s13277-015-3644-3 · Cited by 46 · see citing works

Downregulation of indoleamine-2,3-dioxygenase in cervical cancer cells suppresses tumor growth by promoting natural killer cell accumulation

Sato, N., Saga, Y., Mizukami, H., WANG, D., Takahashi, S., NONAKA, H., Fujiwara, H., Takei, Y., 町田, 静., Takikawa, O., et al. (2012) · Oncology Reports · doi:10.3892/or.2012.1984 · Cited by 46 · see citing works

Prognostic Impact of Tumor-Associated Macrophages on Survival Is Checkpoint Dependent in Classical Hodgkin Lymphoma

Karihtala, K., Leivonen, S., Brück, O. E., Karjalainen‐Lindsberg, M., Mustjoki, S. M., Pellinen, T. S., & Leppä, S. (2020) · Cancers · doi:10.3390/cancers12040877 · Cited by 45 · see citing works

Immune checkpoint blockade reveals the stimulatory capacity of tumor-associated CD103 + dendritic cells in late-stage ovarian cancer

Flies, D. B., Higuchi, T., Harris, J. C., Jha, V., Gimotty, P. A., & Adams, S. F. (2016) · OncoImmunology · doi:10.1080/2162402x.2016.1185583 · Cited by 44 · see citing works

Signaling pathways and therapeutic interventions in gastric cancer

Lei, Z., Teng, Q., Qin, T. L., Chen, W., Xie, Y., Wu, K., Zeng, Q., Zeng, L., Pan, Y., Chen, Z., et al. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01190-w · Cited by 325 · see citing works

Unraveling the tumor microenvironment: Insights into cancer metastasis and therapeutic strategies

El‐Tanani, M., Rabbani, S. A., Babiker, R. A., Rangraze, I. R., Kapre, S., Palakurthi, S. S., Alnuqaydan, A. M., Aljabali, A. A. A., Rizzo, M., El‐Tanani, Y., et al. (2024) · Cancer Letters · doi:10.1016/j.canlet.2024.216894 · Cited by 209 · see citing works

Exosome-Mediated Immunosuppression in Tumor Microenvironments

Xie, Q., Zheng, J.-Q., Ding, J., Wu, Y.-F., Liu, L., Yu, Z., & Chen, G. (2022) · Cells · doi:10.3390/cells11121946 · Cited by 139 · see citing works

Regorafenib plus nivolumab in patients with mismatch repair-proficient/microsatellite stable metastatic colorectal cancer: a single-arm, open-label, multicentre phase 2 study

Fakih, M., Raghav, K. P. S., Chang, D. Z., Larson, T., Cohn, A. L., Huyck, T. K., Cosgrove, D., Fiorillo, J. A., Tam, R., D’Adamo, D. R., et al. (2023) · EClinicalMedicine · doi:10.1016/j.eclinm.2023.101917 · Cited by 120 · see citing works

Mechanisms of immune modulation in the tumor microenvironment and implications for targeted therapy

Czajka‐Francuz, P., Prendes, M. J., Mankan, A. K., Quintana, Á., Pabla, S., Ramkissoon, S. H., Jensen, T. J., Peiró, S., Severson, E. A., Achyut, B. R., et al. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1200646 · Cited by 69 · see citing works

Immune-Checkpoint Inhibitors (ICIs) in Metastatic Colorectal Cancer (mCRC) Patients beyond Microsatellite Instability

Borelli, B., Antoniotti, C., Carullo, M., Germani, M. M., Conca, V., & Masi, G. (2022) · Cancers · doi:10.3390/cancers14204974 · Cited by 62 · see citing works

Integrating single-cell analysis and machine learning to create glycosylation-based gene signature for prognostic prediction of uveal melanoma

Liu, J.-L., Zhang, P., Yang, F., Jiang, K., Sun, S., Xia, Z., Yao, G., & Tang, J. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1163046 · Cited by 59 · see citing works

Multifunctional nanocomposites modulating the tumor microenvironment for enhanced cancer immunotherapy

Sharma, P., & Otto, M. (2023) · Bioactive Materials · doi:10.1016/j.bioactmat.2023.08.022 · Cited by 59 · see citing works

Dendritic cell-derived exosomes: A new horizon in personalized cancer immunotherapy?

Ghorbaninezhad, F., Alemohammad, H., Najafzadeh, B., Masoumi, J., Shadbad, M. A., Shahpouri, M., Saeedi, H., Rahbarfarzam, O., & Baradaran, B. (2023) · Cancer Letters · doi:10.1016/j.canlet.2023.216168 · Cited by 43 · see citing works

Recent advances in exosome-based immunotherapy applied to cancer

Xie, J., Zheng, Z., Tuo, L., Deng, X., Tang, H., Peng, C., & Zou, Y. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1296857 · Cited by 41 · see citing works

Extracellular vesicles at the crossroad between cancer progression and immunotherapy: focus on dendritic cells

Schioppa, T., Gaudenzi, C., Zucchi, G., Piserà, A., Vahidi, Y., Tiberio, L., Sozzani, S., Prete, A. D., Bosisio, D., & Salvi, V. (2024) · Journal of Translational Medicine · doi:10.1186/s12967-024-05457-4 · Cited by 39 · see citing works

Current and Future Trends of Colorectal Cancer Treatment: Exploring Advances in Immunotherapy

Nikolouzakis, T. K., Chrysos, E., Docea, A. O., Fragkiadaki, P., Souglakos, J., Tsiaoussis, J., & Tsatsakis, A. (2024) · Cancers · doi:10.3390/cancers16111995 · Cited by 37 · see citing works

Biomimetic nanoparticles for tumor immunotherapy

Yu, H., Wu, M., Chen, S., Song, M., & Yue, Y. (2022) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2022.989881 · Cited by 32 · see citing works

Macrophage-associated immune checkpoint CD47 blocking ameliorates endometriosis

Li, J., Yan, S., Li, Q., Huang, Y., Ji, M., Jiao, X., Yuan, M., & Wang, G. (2022) · Molecular Human Reproduction · doi:10.1093/molehr/gaac010 · Cited by 32 · see citing works

CTLA-4 silencing in dendritic cells loaded with colorectal cancer cell lysate improves autologous T cell responses in vitro

Ghorbaninezhad, F., Masoumi, J., Bakhshivand, M., Baghbanzadeh, A., Mokhtarzadeh, A., Kazemi, T., Maleki, L. A., Shotorbani, S. S., Jafarlou, M., Brunetti, O., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.931316 · Cited by 31 · see citing works

Cytokine Networks as Targets for Preventing and Controlling Chagas Heart Disease

Koh, C. C., Neves, E. G. A., Silva, T. G. D. S. E., Carvalho, A. C., Pinto, C. H. R., Galdino, A. S., Gollob, K. J., & Dutra, W. O. (2023) · Pathogens · doi:10.3390/pathogens12020171 · Cited by 29 · see citing works

A literature review of recent advances in gastric cancer treatment: exploring the cross-talk between targeted therapies

Panahizadeh, R., Panahi, P., Asghariazar, V., Makaremi, S., Noorkhajavi, G., & Safarzadeh, E. (2025) · Cancer Cell International · doi:10.1186/s12935-025-03655-8 · Cited by 24 · see citing works

A mesoporous gold biosensor to investigate immune checkpoint protein heterogeneity in single lung cancer cells

Ahmed, E., Masud, M. K., Komatineni, P., Dey, S., Lobb, R. J., Hossain, M. S. A., Möller, A., Yamauchi, Y., Sina, A. A. I., & Trau, M. (2024) · Biosensors and Bioelectronics · doi:10.1016/j.bios.2023.115984 · Cited by 23 · see citing works

The Cellular and Molecular Immunotherapy in Prostate Cancer

Mukherjee, A. G., Wanjari, U. R., Prabakaran, D. S., Ganesan, R., Renu, K., Dey, A., Vellingiri, B., Kandasamy, S., Ramesh, T., & Gopalakrishnan, A. V. (2022) · Vaccines · doi:10.3390/vaccines10081370 · Cited by 23 · see citing works

T-cell immunoglobulin and ITIM domain in cancer immunotherapy: A focus on tumor-infiltrating regulatory T cells

Xiaoyan, T., Ning, Q., Yu, J., & Tang, S. (2022) · Molecular Immunology · doi:10.1016/j.molimm.2022.04.014 · Cited by 22 · see citing works

CD33 Expression on Peripheral Blood Monocytes Predicts Efficacy of Anti-PD-1 Immunotherapy Against Non-Small Cell Lung Cancer

Olingy, C. E., Alimadadi, A., Araujo, D. J., Barry, D., Gutierrez, N. A., Hardy-Werbin, M., Arriola, E., Patel, S. P., Ottensmeier, C. H. H., Dinh, H. Q., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.842653 · Cited by 20 · see citing works

Targeting the prostate tumor microenvironment by plant-derived natural products

Wu, J., Ji, H., Li, T., Guo, H., Xu, H., Zhu, J., Tian, J., Gao, M., Wang, X., & Zhang, A. (2023) · Cellular Signalling · doi:10.1016/j.cellsig.2023.111011 · Cited by 19 · see citing works

Jianpi Yangzheng Xiaozheng decoction alleviates gastric cancer progression via suppressing exosomal PD-L1

Chen, Y., Liu, J., Chen, Y., Zhang, R., Tao, J., Chen, Y., Wang, H., Sun, Q., Wu, J., & Liu, S. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1159829 · Cited by 18 · see citing works

Advances in immunotherapy for breast cancer and feline mammary carcinoma: From molecular basis to novel therapeutic targets

Vilela, T., Valente, S., Correia, J., & Ferreira, F. (2024) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2024.189144 · Cited by 19 · see citing works

Sustained and specific multiplexed immune checkpoint modulation in CAR T cells induced by targeted epigenome editing

Azcona, M. S. R., Monaco, G., Whitehead, M., Kaufmann, M. M., Alzubi, J., Cathomen, T., & Mussolino, C. (2025) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2025.102618 · Cited by 17 · see citing works

Characterization of Aging-Related Genes to Predict Prognosis and Evaluate the Tumor Immune Microenvironment in Malignant Melanoma

Zeng, N., Guo, C., Wang, Y., Li, L., Chen, X., Gao, S., Jiang, F., & Cao, B. (2022) · Journal of Oncology · doi:10.1155/2022/1271378 · Cited by 17 · see citing works

Aspirin prevents colorectal cancer by regulating the abundance of Enterococcus cecorum and TIGIT+Treg cells

Yang, X., Yan, Y., Wang, F., Tian, J., Cao, Q., Liu, M., Ma, B., Su, C., & Duan, X. (2024) · Scientific Reports · doi:10.1038/s41598-024-64447-0 · Cited by 17 · see citing works

Advancements in Immunotherapeutic Treatments for Hepatocellular Carcinoma: Potential of Combination Therapies

Zarlashat, Y., Mushtaq, H., Pham, L., Abbas, W., & Sato, K. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25136830 · Cited by 19 · see citing works

Tumor-Infiltrating B Lymphocytes: Promising Immunotherapeutic Targets for Primary Liver Cancer Treatment

Milardi, G., & Lleò, A. (2023) · Cancers · doi:10.3390/cancers15072182 · Cited by 16 · see citing works

Cancer-Related Immune Therapies

Miteva, K., Anker, M. S., Fechner, H., Lehmann, L., & Linthout, S. V. (2025) · JACC CardioOncology · doi:10.1016/j.jaccao.2025.06.008 · Cited by 16 · see citing works

The evolving landscape of antibody-based cancer therapies: From monospecific to multi-specific and beyond

Okpasuo, O. J., Olaoba, O. T., Bokolo, P., Aleke, A. S., Dare, A., Adelusi, T. I., & Jackson, C. D. (2025) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2025.105037 · Cited by 14 · see citing works

Immunotherapy through the Lens of Non-Small Cell Lung Cancer

Stanley, R., Flanagan, S., Reilly, D. E. O., Kearney, E., Naidoo, J., & Dowling, C. M. (2023) · Cancers · doi:10.3390/cancers15112996 · Cited by 16 · see citing works

Alternative Strategies for Delivering Immunotherapeutics Targeting the PD-1/PD-L1 Immune Checkpoint in Cancer

Hoshi, R., Gorospe, K. A., Labouta, H. I., Azad, T., Lee, W. L., & Thu, K. L. (2024) · Pharmaceutics · doi:10.3390/pharmaceutics16091181 · Cited by 15 · see citing works

Prognostic significance of the immune checkpoint HLA-G/ILT-4 in the survival of patients with gastric cancer

Chen, Q.-Y., Zhou, W., Zhang, J.-G., Zhang, X., Han, Q.-Y., Lin, A., & Yan, W. (2022) · International Immunopharmacology · doi:10.1016/j.intimp.2022.108798 · Cited by 13 · see citing works

Progress and prospects of biomarker-based targeted therapy and immune checkpoint inhibitors in advanced gastric cancer

Zeng, Z., & Zhu, Q. C. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1382183 · Cited by 12 · see citing works

Monocyte-derived Galectin-9 and PD-L1 differentially impair adaptive and innate immune response in chronic HBV infection and their expression remain unaltered after antiviral therapy

Dey, D., Biswas, S., Pal, S., Nandi, S., Khatun, N., Jha, R., Chakraborty, B. C., Baidya, A., Ghosh, R., Banerjee, S., et al. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1474853 · Cited by 12 · see citing works

Revealing the role of regulatory b cells in cancer: development, function and treatment significance

Ye, R., Li, S., Li, Y., Shi, K., & Li, L. (2025) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-025-03973-w · Cited by 12 · see citing works

Tumor-infiltrating lymphocytes predict efficacy of immunotherapy in advanced non-small cell lung cancer: a single-center retrospective cohort study

Zhang, W., Li, S., Zhang, C., Mu, Z., Chen, K., & Xu, Z. (2023) · Acta Oncologica · doi:10.1080/0284186x.2023.2228991 · Cited by 11 · see citing works

A comprehensive pan-cancer analysis of RNF187 in human tumors

Zhang, X., Zhang, X., Liu, T., & Sha, K. (2025) · Discover Oncology · doi:10.1007/s12672-025-01795-x · Cited by 10 · see citing works

Construction and validation of a cuproptosis-related lncRNA signature for the prediction of the prognosis of LUAD and LUSC

Wang, Y., Xiao, X., & Li, Y. (2023) · Scientific Reports · doi:10.1038/s41598-023-29719-1 · Cited by 10 · see citing works

Enhanced thrombopoiesis supplies PD-L1 to circulating immune cells via the generation of PD-L1-expressing platelets in patients with lung cancer

Lee, S., Jeong, S., Kim, Y. J., Noh, J. E., Rho, K. N., Kim, H.-O., Cho, H.-J., Yang, D., Hwang, E. C., Bae, W. K., et al. (2025) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2024-010193 · Cited by 9 · see citing works

Understanding the regulation of “Don’t Eat-Me” signals by inflammatory signaling pathways in the tumor microenvironment for more effective therapy

Karizak, A. Z., Salmasi, Z., Hayat, S. M. G., Asadi, M., Ghasemi, Y., Tajbakhsh, A., & Savardashtaki, A. (2022) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-022-04452-w · Cited by 9 · see citing works

Contribution of the TIM-3/Gal-9 immune checkpoint to tropical parasitic diseases

Bailly, C. (2022) · Acta Tropica · doi:10.1016/j.actatropica.2022.106792 · Cited by 9 · see citing works

Mechanism of Action of Oral Salmonella-Based Vaccine to Prevent and Reverse Type 1 Diabetes in NOD Mice

Cobb, J., Rawson, J., Gonzalez, N., Singer, M., KANDEEL, F. R., & Husseiny, M. I. (2024) · Vaccines · doi:10.3390/vaccines12030276 · Cited by 9 · see citing works

Small non-coding RNAs: key regulatory factors and potential therapeutic targets in tumor immunity

Liu, Z., Dong, H., Ye, C., Yan, J., Miao, M., & Shao, Y. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1639763 · Cited by 8 · see citing works

Identification of the Prognostic Biomarkers CBX6 and CBX7 in Bladder Cancer

Li, X., Li, L., Xiong, X., Kuang, Q., Peng, M., Zhu, K., & Luo, P. (2023) · Diagnostics · doi:10.3390/diagnostics13081393 · Cited by 8 · see citing works

Ansofaxine suppressed NSCLC progression by increasing sensitization to combination immunotherapy

Gui, H., Nie, Y., 袁, 豪., Wang, M., Li, L., Zhu, L., Chen, S., Jing, Q., Wan, Q., Lv, H., et al. (2024) · International Immunopharmacology · doi:10.1016/j.intimp.2024.113918 · Cited by 7 · see citing works

Neuro-ophthalmic complications of modern anti-cancer drugs

Oskam, J. A., & Danesh-Meyer, H. V. (2024) · Graefe s Archive for Clinical and Experimental Ophthalmology · doi:10.1007/s00417-023-06350-4 · Cited by 7 · see citing works

The emerging role of TIM-3 in colorectal cancer: a promising target for immunotherapy

Karami, R., Fathi, M., Jalali, P., Hassannia, H., Zarei, A., Hojjat‐Farsangi, M., & Jadidi‐Niaragh, F. (2024) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2024.2442437 · Cited by 6 · see citing works

Immunomodulatory and antioxidant effect of liposomal auraptene against cyclophosphamide-induced immunosuppression in BALB/c mice

Naseri, S., Asgarpanah, J., & Ziai, S. A. (2024) · Experimental Gerontology · doi:10.1016/j.exger.2024.112552 · Cited by 6 · see citing works

Siglec15 in blood system diseases: from bench to bedside

Fan, Y., Sun, L., He, J., Chen, Y., Ma, H., & Ding, H. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1490505 · Cited by 5 · see citing works

MicroRNA 320a-3p up-regulation reduces PD-L1 expression in gastric cancer cells: an experimental and bioinformatic study

Asghariazar, V., Makaremi, S., Amani, N., Zare, E., Kadkhodayi, M., Eterafi, M., Golmohammadi, M. G., & Safarzadeh, E. (2025) · Scientific Reports · doi:10.1038/s41598-025-92537-0 · Cited by 5 · see citing works

Unmasking the Rare but Lethal Cardiac Complications of Immune Checkpoint Inhibitor Therapy: A Review of Mechanisms, Risk Factors, and Management Strategies

Chehade, L., Abbas, N., Dagher, K., Mourad, M., Amhez, G., Moumneh, M. B., Kreidieh, L., Kreidieh, F., Pereira, M. M. A. M., & Shamseddine, A. I. (2025) · Current Treatment Options in Oncology · doi:10.1007/s11864-025-01329-1 · Cited by 5 · see citing works

Dendritic cells-derived extracellular vesicles in tumourigenesis: From biological roles to clinical implications

Chen, Q., Wang, W., He, X., Wang, C., Guo, H., & Ou, C. (2025) · Cancer Letters · doi:10.1016/j.canlet.2025.218034 · Cited by 6 · see citing works

Self-Adjuvanting Gel for Hierarchical Delivery to Tumors and Lymph Nodes in Liver and Colon Tumor Immunotherapy

Liu, C., Gao, Y., Qi, Y., Zhu, Z., Liu, L., Lv, K., Lin, X., Yu, Y., Si, X., Song, W., et al. (2025) · ACS Nano · doi:10.1021/acsnano.5c11500 · Cited by 5 · see citing works

Investigation of LGALS2 expression in the TCGA database reveals its clinical relevance in breast cancer immunotherapy and drug resistance

He, S., Ji, Z., Zhang, Q. H., Zhang, X., Chen, J., Hu, J., Wang, R., & Ding, Y. (2023) · Scientific Reports · doi:10.1038/s41598-023-44777-1 · Cited by 5 · see citing works

Network Pharmacological Analysis and Experimental Validation of the Effects of Silybin on Proliferation, Migration, and Immunotherapy of Papillary Thyroid Cancer

Xie, W., Li, H., Lin, Q., & Ke, N. (2023) · Endocrine Metabolic & Immune Disorders - Drug Targets · doi:10.2174/0118715303248000230922185110 · Cited by 5 · see citing works

A bibliometric analysis of global research trends of inflammation in cervical cancer: A review

Kang, M., Qiu, J., Wei, H., & Li, J. (2023) · Medicine · doi:10.1097/md.0000000000036598 · Cited by 6 · see citing works

Targeting “don’t eat me” signal: breast cancer immunotherapy

Gao, Y., Zhang, X., Ding, M., Fu, Z., & Zhong, L. (2025) · Breast Cancer Research and Treatment · doi:10.1007/s10549-025-07659-w · Cited by 4 · see citing works

Machine learning–based new classification for immune infiltration of gliomas

Yuan, F., Wang, Y., Yuan, L., Ye, L., Hu, Y., Cheng, H., & Li, Y. (2024) · PLoS ONE · doi:10.1371/journal.pone.0312071 · Cited by 4 · see citing works

NGEF is a potential prognostic biomarker and could serve as an indicator for immunotherapy and chemotherapy in lung adenocarcinoma

Chen, X., Zhang, T., He, Y., Miao, T., Yin, J., Ding, Q., Yang, M., Chen, F.-Y., Zeng, H., Liu, J., et al. (2024) · BMC Pulmonary Medicine · doi:10.1186/s12890-024-03046-1 · Cited by 4 · see citing works

Success stories: impactful applications of cancer biomarkers

Theivendren, P., Kunjiappan, S., Pavadai, P., Shanmugam, A., Karunanithi, K., Gopal, M., & Kiruthiga, N. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-29279-8.00015-6 · Cited by 3 · see citing works

Exosome: The hidden messengers in cancer detection and immunotherapy

Sultana, F., & Ghosh, A. (2025) · Urologic Oncology Seminars and Original Investigations · doi:10.1016/j.urolonc.2025.07.006 · Cited by 3 · see citing works

Integrated Multi-Omics Approaches for Predicting Immune Checkpoint Inhibitor Response in NSCLC – Insights From Genomics, Proteomics, and Metabolomics

Elayeh, E. R., Aleidi, S., Aboud, O., Semreen, M., Bustanji, Y., & Dahabiyeh, L. (2025) · Lung Cancer Targets and Therapy · doi:10.2147/lctt.s539777 · Cited by 3 · see citing works

SERS-enabled immune monitoring: Decoding the tumor microenvironment for precision Cancer immunotherapy

Chen, B., Gao, J., Sun, H., Chen, Z., & Qiu, X. (2026) · International Immunopharmacology · doi:10.1016/j.intimp.2026.116241 · Cited by 3 · see citing works

Research progress and prospect of tumor nanovaccine combination therapy strategy

Yin, Y., Guo, J., Zhang, S., Xu, M., Fu, Y. Z., Zhang, M., Ma, Z., Ji, J., Wu, S., Zhang, J., et al. (2024) · Chinese Chemical Letters · doi:10.1016/j.cclet.2024.110771 · Cited by 3 · see citing works

A novel prognostic model for lung squamous cell carcinoma based on multi-omics analysis and machine learning

Li, J., Shen, Z., Liu, D., & Ma, J. (2025) · PLoS ONE · doi:10.1371/journal.pone.0336792 · Cited by 3 · see citing works

Construction of a redox-related gene signature for overall survival prediction and immune infiltration in non-small-cell lung cancer

Miao, T., Yang, D., Gao, L.-J., Yin, J., Zhu, Q., Liu, J., He, Y., & Chen, X. (2022) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2022.942402 · Cited by 3 · see citing works

Comprehensive analysis of tertiary lymphoid structures-related genes for prognostic prediction, molecular subtypes and immune infiltration in gastric cancer

Zhou, Q., Lan, L., Wang, W., Xu, X., & Wang, W. (2023) · Aging · doi:10.18632/aging.205247 · Cited by 3 · see citing works

Immune Checkpoint Inhibitors in Cancer Immunotherapy

Hussain, F. H. N., & Raza, A. (2024) · Advances in medical diagnosis, treatment, and care (AMDTC) book series · doi:10.4018/979-8-3693-3976-3.ch004 · Cited by 3 · see citing works

Cytokine Networks and the Clinical Outcome of American Teg-Umentary Leishmaniasis: Unveiling Targets for Alternative Therapeutic Interventions

Koh, C. C., Gollob, K. J., & Dutra, W. O. (2025) · Pathogens · doi:10.3390/pathogens14020188 · Cited by 2 · see citing works

Computational Mapping of Conformational Dynamics and Interaction Hotspots of Human VISTA with pH-Selective Antibodies

Ly, N., Ramgoolam, S. D., & Ganesan, A. (2025) · Biochemistry · doi:10.1021/acs.biochem.4c00863 · Cited by 2 · see citing works

Immune escape mechanisms and therapeutic advances in virus-associated hematological malignancies

Li, T., Wang, C., Xiao, Q., Zhang, X., Zailin, Y., Li, J., & Liu, Y. (2026) · Blood Cancer Journal · doi:10.1038/s41408-026-01453-7 · Cited by 2 · see citing works

A comprehensive review of mucilage polysaccharides with dual immunomodulatory and anti-tumor activities: Mechanisms, structure-activity relationships and application prospects in tumor immunotherapy

Chen, Y. N., 罗晓丁, Wang, Z., Duan, J., & Xiao, P. (2026) · Pharmacological Research · doi:10.1016/j.phrs.2026.108256 · Cited by 1 · see citing works

Tumor-derived extracellular vesicles: From biogenesis and molecular composition to translational therapeutics

Sheikh, S. M., Hussain, U., Meshram, S. S., Yadav, H., Deshmukh, A. D., Dhakare, S. P., Belgamwar, V. S., & Prasad, S. K. (2026) · Pathology - Research and Practice · doi:10.1016/j.prp.2026.156579 · Cited by 2 · see citing works

Real-world landscape transition of death causes in the immunotherapy era for metastatic non-small cell lung cancer

Wu, Y., Yao, Z., Zhang, J., Han, C., Kang, K., & Zhao, A. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1058819 · Cited by 1 · see citing works

Identification of a lipid metabolism-related gene for cancer immunotherapy

Jiang, X., Du, W., Shi, C., Kang, M., Song, Q., Zhang, L., & Pei, D. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1186064 · Cited by 1 · see citing works

Immuno-Oncology In Cancer Cervix Treatments: Literature Review

Naser, M., Nasr, M., & Shehata, L. H. (2023) · International Journal of Progressive Sciences and Technologies · doi:10.52155/ijpsat.v41.1.5708 · Cited by 1 · see citing works

The enigma of LAG3 receptor in hematological malignancies

Kreiniz, N., Polliack, A., & Tadmor, T. (2022) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2022.2133543 · Cited by 1 · see citing works

Belastung, Muskelreparatur, Muskelremodulation, Immunsystem

Laube, W. (2023) · Springer eBooks · doi:10.1007/978-3-662-67753-7_11

P3H1 as a novel prognostic biomarker correlates with immune infiltratePreprint

Wu, C.-M., You, X., Li, B., Wang, Q., Li, M., Wen, J., Yu, L., Jiang, H., Xie, W., Xia, Y., et al. (2024) · Research Square · doi:10.21203/rs.3.rs-3871518/v1

TIM3 or HAVCR2 in Breast Cancer Instead of Suppression May Invoke Immune Action in Tumor Micro EnvironmentPreprint

BASU, A., GHOSH, A., Dolui, B., Majumdar, B., Krishna, P., & Bandopadhaya, A. (2024) · Preprints.org · doi:10.20944/preprints202401.1916.v1

Monocyte derived Galectin-9 and PD-L1 differentially impair innate and adaptive immune response in various phases of chronic HBV infectionPreprint

Dey, D., Biswas, S., Pal, S., Nandi, S., Khatun, N., Jha, R., Chakraborty, B. C., Baidya, A., Ghosh, R., Banerjee, S., et al. (2024) · Research Square · doi:10.21203/rs.3.rs-3954802/v1

Monocyte-Derived Galectin-9 and PD-L1 Differentially Impair Adaptive and Innate Immune Response in Chronic HBV Infection and Their Expression Remain Unaltered after Antiviral TherapyPreprint

Dey, D., Biswas, S., Pal, S., Nandi, S., Khatun, N., Jha, R., Chakraborty, B. C., Baidya, A., Ghosh, R., Banerjee, S., et al. (2024) · SSRN Electronic Journal · doi:10.2139/ssrn.4867538

The temporal evolution of cancer hallmarksPreprint

Zapata, L., Gourmet, L. E., Lam, J. M., Ramazzotti, D., Pennycuick, A., Mallick, P., & Walker‐Samuel, S. (2024) · Research Square · doi:10.21203/rs.3.rs-5499335/v1

Role of immune checkpoint inhibitors in breast cancer and hematological malignancies

Bao, Q., Chen, H., Wu, S., Tian, Z., & Tang, H. (2025) · Exploration of Immunology · doi:10.37349/ei.2025.1003220

Additional file 1 of NGEF is a potential prognostic biomarker and could serve as an indicator for immunotherapy and chemotherapy in lung adenocarcinoma

Chen, X., Zhang, T., He, Y.-Q., Miao, T.-W., Yin, J., Ding, Q., Yang, M., Chen, F.-Y., Zeng, H.-P., Liu, J., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26722695

Neutrophil-related signature characterizes immune landscape and predicts prognosis of esophageal squamous cell carcinoma

Hu, Z., Ye, Z., Guo, Y., & Li, M. (2025) · Open Life Sciences · doi:10.1515/biol-2025-1210

Enhancing the tumoricidal efficacy of the nanobubbles-mediated PD-L1 inhibition and immunogenic cell death in mice

Liu, Y., Han, J., Liu, C., Chen, Y., Yang, S., Ma, Y., Zhou, C., Liu, R., Hu, Y., & Zhao, Y. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1672324

Thyroid Eye Disease-Like Conditions Associated With Cancer and Immune Check Point Blockage: Systematic Literature Review and Case Report

Nakassa, A. C. I., Facchin, M. P. S., Carregaro, V., & Cruz, A. A. V. E. (2026) · Ophthalmic Plastic and Reconstructive Surgery · doi:10.1097/iop.0000000000003184

Innovative immune checkpoint modulators: monoclonal antibodies, small molecules, non-coding RNAs, and nanoparticles in cancer immunotherapy

Jafari, S., Zarredar, H., Ostadrahimi, A., Nakhlband, A., Hosseini, V., Montazersaheb, S., & Alamdari, N. M. (2026) · Cytokine · doi:10.1016/j.cyto.2026.157177

Кардиоваскулотоксичность противоопухолевой терапии ингибиторами иммунных контрольных точек и ингибиторами рецепторов фактора роста эндотелия сосудов: современные представленияPreprint

Загитовна, З. Д. (2026) · doi:10.24108/preprints-3115653

Immune checkpoints and cancer development: Therapeutic implications and future directions

Mehdizadeh, S., Bayatipoor, H., Pashangzadeh, S., Jafarpour, R., Shojaei, Z., & Motallebnezhad, M. (2021) · Pathology - Research and Practice · doi:10.1016/j.prp.2021.153485 · Cited by 55 · see citing works

Targeting immune checkpoints for cancer therapy

Kumari, N., Brahma, M., & Maruthi, M. (2023) · Elsevier eBooks · doi:10.1016/b978-0-443-16034-9.00012-5

Targeting Immune Checkpoints: Basic Signaling Pathways and Clinical Translation in Cancer Therapeutics

Sun, H., Huang, D., Zhang, H., Dong, M., Wang, S., Sun, M., Liu, J., Wang, Y., Qu, X., Li, X., et al. (2025) · MedComm – Oncology · doi:10.1002/mog2.70030 · Cited by 12 · see citing works

Introduction on Immune Checkpoints in Cancer

Balibegloo, M., & Rezaei, N. (2023) · Springer eBooks · doi:10.1007/978-3-030-80962-1_158-1 · Cited by 1 · see citing works

Immune Checkpoint Molecules and Cancer Immunotherapy

Karakhanova, S., Amedei, A., & Bazhin, A. V. (2019) · Directory of Open access Books (OAPEN Foundation)